ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO951

A Retrospective View of the Relationship of Soluble Fas with Anemia and Outcomes in CKD

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism


  • Andrade, Jessica Liara Felicio de, Universidade Federal de Sao Paulo, Sao Paulo, Sao Paulo, Brazil
  • Clemente, Otavio Henrique, Universidade Federal de Sao Paulo, Sao Paulo, Sao Paulo, Brazil
  • Silva, Beatriz Moreira, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
  • Rodrigues, Adelson, Universidade Federal de Sao Paulo, Sao Paulo, Sao Paulo, Brazil
  • Zarjou, Abolfazl, The University of Alabama at Birmingham Center for the Study of Community Health, Birmingham, Alabama, United States
  • Goes, Miguel Angelo, Sociedade Beneficente Israelita Brasileira Albert Einstein, Sao Paulo, São Paulo, Brazil

Anemia is common in chronic kidney disease (CKD) and is related to serum levels of soluble Fas (sFas), which are associated with resistance to erythropoietin (EPO). The study objeticves to compare clinical data and serum levels of sFas, EPO, and pro- inflammatory markers between non-dialytic CKD patients and healthy individuals. To assess the relationship of serum EPO and sFas between these patients with and without anemia.


Retrospective study of 58 CKD patients under conservative treatment and 20 healthy individuals. Complete blood count, renal function, serum EPO, sFas, and inflammatory markers (CRP, IL-6, and IFN-γ) were compared at baseline. We then analyzed these variables between patients who progressed to anemia and those without anemia. We evaluated the frequency of outcomes in these patients with elevated sFas levels. We performed a multivariate analysis of factors associated with anemia.


CKD when compared to healthy individuals had lower eGFR (35.7 ±2.5 vs 89.7 ±3.32 ml/min; p<0.001), and Hb (12.8 ±0.27 vs 14.4 ± 0.25 g/dl; p=0.003), major inflammatory markers, sFas (2894 ±172 vs 1136 ±97pg/ml; p<0.001), and EPO/Hb (8.76 ±1.16 vs 4.90 ± 0.58 IU/mg/dl; p=0.003). CKD with anemia, when compared to non-anemic individuals, had lower eGFR (27.7 ±1.72 vs 54.9 ±5.26; p<0.001) and higher sFas/ eGFR (150.9 ±16.6 vs 45.2 ±9.95; p<0.001), EPO/Hb (10.3 ±1.56 vs 5.12 ±0.69; p=0.04) and sFas (3339 ±181 vs 1820 ±240; p=0.001). We found an independent association in the multivariate analysis of serum sFas levels with long-term renal anemia sFas (OR 4.322, 95% CI, 1464-12.753; p=0.008).


As an elective risk factor, serum sFas levels were independently associated with long-term renal anemia.


  • Other NIH Support